Our investigation indicates that pretreatment of human immunoglobulin for the elimination of the anticomplementary activity is associated with a loss of activity, the extent of which depends on the type of treatment applied. Laboratory preparations of human IgG were tested in a mouse protection assay using influenza A2-Taiwan virus, tetanus toxin and Salmonella typhimurium as the challenge. There was a 7-28% reduction in efficacy in an intravenous 7S preparation in comparison with an untreated 7S IgG. F(ab')2 fragments showed a 24-65% and Fab fragments an 80-100% reduction in efficacy. Two commercial human 7S products showed approximately 90% efficacy in the Salmonella assay; a commercial, pepsin-treated preparation showed 65-74% efficacy when compared with untreated 7S IgG.

Animals↗

PubMedDate not supplied

Re: Prophylaxis of gram-negative and gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with pseudomonas immunoglobulin and ciprofloxacin.

Explore the source record for details and available documents.

Animals↗

PubMedDate not supplied

Non-A, non-B hepatitis from intravenous immunoglobulins.

Explore the source record for details and available documents.

Hepatitis C↗

PubMedDate not supplied

beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives.

The efficacy of combined beta-propiolactone/ultraviolet irradiation (betaPL/UV) for inactivation of hepatitis B virus in labile blood derivatives has been reviewed. The initial evaluations of these procedures were hampered by inadequate process control that resulted in excessive protein denaturation; furthermore, adequate evaluation of process efficacy for virus inactivation was prevented by the absence of titered hepatitis virus stocks, the lack of an animal model, and the failure to carry out controlled trials. Finally, it was not appreciated that the power of these procedures lay especially in their use in combination. These deficits have now been remedied. To permit quantitation of process efficacy, a regression analysis of the relation between virus dose and incubation period in chimpanzees has been carried out. This has provided a means of estimating virus titer and determining the accuracy of such estimates. The most recent data suggest that betaPL/UV can reduce the titer of hepatitis B virus about 10 million fold (10(-7)). The process efficacy for betaPL/UV followed by the special adsorption procedures used in preparation of a stabilized human serum containing most human serum proteins except for factor VIII, the factor IX complex, fibrinogen, and the lipoproteins was estimated as a 10(8)-fold reduction in virus titer. This degree of virus inactivation should be more than sufficient to sterilize the amounts of hepatitis B virus that could be expected in pooled human plasma that has been screened for hepatitis B surface antigen. Preliminary data also suggest that the betaPL/UV procedure effectively inactivates non-A, non-B hepatitis virus(es).

Animals↗